Pacira BioSciences Cash Flow Statement
NASDAQ: PCRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Pacira BioSciences free cash flow
In fiscal 2025, Pacira BioSciences generated $152.0 million of operating cash flow and spent $15.3 million on capital expenditures. That left free cash flow of $136.7 million, a free-cash-flow margin of 18.8% of revenue. Free cash flow was down 23.5% from the prior year's $178.8 million.
Pacira BioSciences returned $148.3 million to shareholders through share repurchases, equal to 109% of free cash flow.
Summary generated from market data by MetaCap's automated system. Methodology
Pacira BioSciences cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 7.03M | -99.56M | 41.95M | 15.91M | 41.98M | 145.52M | -11.02M | -471.00K | -42.61M | -37.95M |
| Net Income growth (YoY) | — | -337.30% | +163.72% | -62.10% | -71.15% | — | — | — | — | -2144.67% |
| Depreciation & Amortization | 91.02M | 78.78M | 75.57M | 91.50M | 28.55M | 19.91M | 19.58M | 13.16M | 13.83M | 12.92M |
| Stock-Based Compensation | 57.50M | 51.17M | 47.90M | 48.09M | 42.25M | 39.92M | 33.65M | 31.73M | 31.60M | 31.25M |
| Change in Working Capital | -45.12M | -22.82M | -19.16M | 3.42M | -24.00M | -18.39M | -28.98M | -16.06M | -6.22M | 19.79M |
| Operating Cash Flow | 151.99M | 189.39M | 154.65M | 145.27M | 125.72M | 77.03M | 70.52M | 48.87M | 17.79M | 33.45M |
| Capital Expenditures | -15.33M | -10.64M | -15.16M | -30.08M | -45.87M | -37.80M | -10.16M | -14.51M | -19.27M | -24.71M |
| Investing Cash Flow | 99.48M | -83.28M | 77.54M | -225.19M | -20.79M | -277.61M | -128.49M | 20.58M | -223.76M | -61.75M |
| Share Repurchases | -148.33M | -25.00M | 0 | 0 | — | — | — | — | — | — |
| Debt Issued | — | — | — | — | — | — | — | — | — | -4.00K |
| Financing Cash Flow | -369.63M | 17.36M | -183.03M | -401.53M | 380.69M | 222.30M | 3.67M | 8.95M | 224.16M | 7.26M |
| Net Change in Cash | -118.23M | 123.48M | 49.16M | -481.44M | 485.62M | 21.73M | -54.30M | 78.40M | — | — |
| Free Cash Flow | 136.66M | 178.75M | 139.49M | 115.20M | 79.85M | 39.23M | 60.36M | 34.36M | -1.48M | 8.74M |
This table shows 10 annual periods of Pacira BioSciences's cash flow statement, from FY 2025 back to FY 2016, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow PCRX's reporting calendar. What is a cash flow statement?